Citations 1
A phase 2 study of IPI-926, an oral hedgehog inhibitor, in patients with myelofibrosis.
Sasaki, Koji , Kelly, Patrick, Kutok, Jeffrey L., Sasaki, Koji , Gotlib, Jason , Mesa, Ruben A. , Ravandi, Farhad , Cortes, Jörge E. , Kantarjian, Hagop M. , Verstovšek, Srđan
Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 7111-7111
